Dlk1-targeting antibodies and uses thereof
OwnerYu Chen, Ping Chi +9inventors
InventorsYu Chen, Ping Chi, Jason S. Lewis, Salomon Tendler, Patricia Manuela Ribeiro Pereira, Yuedan Chen, Juan Yan, Ivo Lorenz, David Andrew, Yazen Jmeian, Woo Hyun Cho
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to Delta Like Non-Canonical Notch Ligand 1 (DLK1). The antibodies of the present technology are useful in methods for detecting and treating a DLK1-associated cancer in a subject in need thereof.
Claims32
An antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein
- (i) the VH comprises a VH-CDR1 sequence comprising SEQ ID NO:
- 3, a VH-CDR2 sequence comprising SEQ ID NO:
- 4, and a VH-CDR3 sequence comprising SEQ ID NO:
- 5, respectively, and the VL comprises a VL-CDR1 sequence comprising SEQ ID NO:
- 8, a VL-CDR2 sequence comprising YAS, and a VL-CDR3 sequence comprising SEQ ID NO:
- 10, respectively;
- or
- (ii) the VH comprises a VH-CDR1 sequence comprising SEQ ID NO:
- 13, a VH-CDR2 sequence comprising SEQ ID NO:
- 14, and a VH-CDR3 sequence comprising SEQ ID NO:
- 15, respectively, and the VL comprises a VL-CDR1 sequence comprising SEQ ID NO:
- 18, a VL-CDR2 sequence comprising FAS, and a VL-CDR3 sequence comprising SEQ ID NO:
- 20, respectively;
- or
- (iii) the VH comprises a VH-CDR1 sequence comprising SEQ ID NO:
- 13, a VH-CDR2 sequence comprising SEQ ID NO:
- 14, and a VH-CDR3 sequence comprising SEQ ID NO:
- 15, respectively, and the VL comprises a VL-CDR1 sequence comprising SEQ ID NO:
- 21, a VL-CDR2 sequence comprising FAS, and a VL-CDR3 sequence comprising SEQ ID NO:
- 20, respectively;
- or
- (iv) the VH comprises a VH-CDR1 sequence comprising SEQ ID NO:
- 13, a VH-CDR2 sequence comprising SEQ ID NO:
- 14, and a VH-CDR3 sequence comprising SEQ ID NO:
- 15, respectively, and the VL comprises a VL-CDR1 sequence comprising SEQ ID NO:
- 22, a VL-CDR2 sequence comprising FAS, and a VL-CDR3 sequence comprising SEQ ID NO:
- 20, respectively.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating cancer in a patient in need thereof comprising
- administering an effective amount of an anti-DLK1 antibody or antigen binding fragment to the patient,
- wherein mRNA and/or polypeptide expression and/or activity levels of PRC2 in a biological sample obtained from the patient are reduced compared to a control sample obtained from a healthy subject or a predetermined threshold.
(canceled)
(canceled)
(canceled)
A kit comprising
- (a) a murine antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable domain (VH) amino acid sequence of SEQ ID NO:
- 1 and a light chain immunoglobulin variable domain (VL) amino acid sequence of SEQ ID NO:
- 6 (J17),
- (b) a chimeric antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable domain (VH) amino acid sequence of SEQ ID NO:
- 11 or SEQ ID NO:
- 23 and a light chain immunoglobulin variable domain (VL) amino acid sequence of SEQ ID NO:
- 16 or SEQ ID NO:
- 27 (I18), and
- (c) an anti-mouse secondary antibody conjugated to a detectable label.
Dependencies are inferred from the claim text.